top of page
Search
Severe asthma biologic access criteria should consider long-term oral corticosteroid (LTOCS) users with low blood eosinophil counts (BEC): Implications of STAR study
The real-world study, “ Biomarker profile and disease burden associated with intermittent and long-term oral corticosteroid use in...
Jun 12, 20253 min read
Minimizing Steroid Burden in Severe Asthma: Real-World Data Demonstrate Biologics as a Game Changer
Drawing on data from over 5,600 severe asthma patients across real-world specialist and primary care settings in 22 countries, the SOLAR...
Jun 4, 20253 min read
New update from the International Severe Asthma Registry (ISAR)!
New real-world insights from the International Severe Asthma Registry (ISAR), spanning data from over 25 countries, have been featured in...
May 21, 20251 min read
Biologics for asthma prevent new-onset diabetes, major adverse cardiovascular events (MACE) as well as other oral corticosteroid (OCS)-related adverse events: Ground-breaking results from SOLAR II
The real-world SOLAR II study shows that biologic initiators had 18% lower risk of developing any oral corticosteroid (OCS)-related...
May 19, 20253 min read
Switching or stopping biologic therapy was associated with worse clinical outcomes than continuing the initial therapy: Results from CLEAR
A recently published study in Pragmatic and Observational Research, “Real-world biologic use patterns in severe asthma, 2015–2021: the...
Mar 18, 20253 min read
Global disease burden of patients with severe asthma, regardless of biologic accessibility and receipt of biologic treatment: Results from EVEREST
The EVEREST study published in the Journal of Asthma and Allergy, “Disease Burden and Access to Biologic Therapy in Patients with Severe...
Dec 16, 20243 min read
bottom of page